T he protein C (PC) pathway plays a major role in inhibiting blood coagulation. PC is activated on the surface of vascular endothelial cells by the thrombin-thrombomodulin (TM) complex. The endothelial PC receptor (EPCR), a receptor which binds circulating PC and presents it to the thrombin-TM complex, enhances PC activation by ≈8-fold in vitro 1 and by ≈20-fold in vivo. 2 Activated PC (APC), in conjunction with its cofactor protein S, degrades coagulation cofactors Va and VIIIa, thereby attenuating thrombin generation.
Hereditary thrombophilia is identified in about one third of patients with unprovoked venous thromboembolism (VTE). 3 Most hereditary thrombophilic defects are related to decreased levels of anticoagulant proteins (eg, deficiencies of PC, protein S, or antithrombin) or gain of function in procoagulant factors (eg, increased levels of prothrombin, factor VIII, or other coagulation factors). 4, 5 Family history is a strong risk factor for VTE, suggesting that many more patients with unprovoked VTE have as yet unidentified genetic abnormalities that predispose them to thrombosis. Identification of these abnormalities is important because it enables more comprehensive counseling of patients and family members, including more vigilant use of VTE prophylaxis in high-risk situations (eg, prolonged immobility perioperatively) and avoidance of estrogen therapy. 4, 5 The presence of thrombophilia, if it were a strong predictor of recurrent VTE, could also influence the duration of anticoagulation therapy.
PC deficiency is generally subdivided into 2 types. Type I deficiencies are characterized by decreases in PC antigen, whereas type II deficiencies are characterized by abnormal biological activity. Abnormal PC activity can be assessed by amidolytic assays (which can detect abnormalities in the serine protease domain of PC) 6 and by coagulation tests, such as those based on the activated partial thromboplastin time. In both the amidolytic and the clotting assays, the PC is commonly converted to APC by protac, an activator found in snake venom. 7, 8 In vivo, however, the conversion of PC to APC is accelerated by the binding of PC to EPCR on the vascular endothelial cell surface. 9 Thus, genetic mutations that impair PC-EPCR interactions would escape detection with currently available diagnostic assays.
PC contains a Gla domain (which contains 9 γ-carboxylated glutamic acid residues), a connecting region, 2 EGF-like domains, an activation peptide, and the serine protease domain. 10, 11 According to the crystal structure, the majority of PC residues contributing to EPCR binding are located on the ω-loop of the Gla domain 12 (which is encoded by exon 3 of the PC gene). EPCR consists of an α1 and α2 domain, which forms a ligand-binding groove composed of 2 antiparallel α-helices that sit on an 8-stranded β-sheet platform. 12 Mutagenesis studies of EPCR and the EPCR crystal structure have shown that the PC-binding domain is located at the distal end of the 2 α-helical segments 12, 13 (encoded by exons 2 and 3 of the EPCR gene).
We hypothesized that mutations that impair PC-EPCR interactions may be associated with an increased risk of VTE. To explore this possibility, we sequenced the PC gene (PROC) and EPCR genes (PROCR) in 657 patients with unprovoked VTE (from the Extended Low-intensity Anticoagulation for Thrombo-embolism [ELATE] trial that compared low-intensity and conventional-intensity anticoagulation with warfarin for the prevention of recurrent VTE) 14 and in 627 controls with no known history of VTE. We focused our DNA sequencing on the following regions: (1) exon 3 of PROC (which encodes for the Gla domain of PC, the region of PC that binds to EPCR), (2) exons 2 and 3 of PROCR (which encode the PC-binding domain of EPCR), and (3) exon 4 of PROCR (which contains the previously reported EPCR A3 haplotype polymorphism site). The EPCR A3 haplotype is associated with reduced EPCR function because of increased endothelial shedding of EPCR. 15, 16 This study is the first targeted DNA gene sequencing analyses of the PROC and PROCR genes in a large group of patients with unprovoked VTE.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
A total of 653 warfarin-treated patients with unprovoked VTE were included in this study (mean age, 57±15 years; 45% women). VTE had occurred once in 27%, twice in 51%, more than twice in 22%, and the most recent episode of VTE was proximal deep vein thrombosis only in 66% and pulmonary embolism (with or without deep vein thrombosis) in 34%. 14 The 627 controls who never had VTE (described in the Materials and Methods in the online-only Data Supplement) had a mean age of 42±9 years, and 49% were women.
To analyze the EPCR-binding domain of PC, we sequenced a 650-bp fragment of PROC that codes for the Gla domain of PC. A list of all single nucleotide variants (SNVs) or single nucleotide polymorphisms found in this study are summarized in Table 1 according to the Human Genome Variation Society nomenclature. 17 We found 6 SNVs in the 650-bp fragment encompassing the coding region of the Gla domain of PC ( Table 2 ). The first was a C to T transition at nucleotide (nt) 2896, which results in substitution of Arg with Cys at residue −1 in the Gla domain of PC (amino acids are numbered from the N terminus of the mature secreted protein). The second SNV was a C to T transition at nt 2923, which results in an Arg9Cys substitution in the Gla domain of PC. The third SNV was a G to A transition at nt 2998, which results in a Val34Met substitution in the Gla domain of PC. The remaining SNVs were located in intron 2 (C2633G and C2730T). None of these SNVs was present in the controls. We also found common single nucleotide polymorphisms in intron 3 of the PC gene in both the patients and the controls.
Using stable transfections, we expressed wild-type human PC (WT PC) and the 3 PC variants (PCArg-1Cys, PCArg9Cys, and PCVal34Met) in human embryonic kidney (HEK) 293 cells. All cell lines contained similar levels of PC mRNA as assessed by the measurement of real-time polymerase chain reaction (PCR); the PCArg-1Cys, PCArg9Cys, and PCVal34Met cell lines contained 57%, 172%, and 134%, respectively, of mRNA relative to the WT PC cell line. The cell lysates and conditioned medium were then subjected to Western blot analysis. As shown in Figure 1 , WT PC was detected in the cell lysate and in the conditioned medium. The 2 PC bands in the conditioned medium are consistent with the α and β forms of PC, which differ in glycosylation state at Asn329. 18 In contrast, PCArg-1Cys, PCArg9Cys, and PCVal34Met were detected at lower levels in the cell lysates and in the conditioned medium.
To determine whether these PROC mutations result in a type I PC deficiency, we measured PC antigen levels in 21 of the patients with VTE (3 patients had mutations in the Gla domain of the PROC gene and 18 did not). We also measured PC antigen levels in 6 healthy volunteers. As shown in Figure 2 , the mean PC antigen level in the VTE patients without the PROC Gla domain mutations (3.61±0.81 µg/mL) was similar to that in the healthy volunteers (3.88±0.19 µg/mL; P=0. 19 ). In contrast, the mean PC antigen level in the VTE patients with the PROC Gla domain mutations (2.52±0.15 µg/mL) was lower than that in healthy volunteers (P<0.001) and in the VTE patients without the PROC mutations (P=0.037). The PC antigen levels in the patients harboring the Val34Met, Arg9Cys, and Arg-1Cys mutations were 66%, 66%, and 58% of normal levels, respectively, suggesting that these mutations result in a heterozygous type 1 deficiency. Given that the PROC mutations are located in the Gla domain of PC, it is also possible that these mutations result in a heterozygous type IIb deficiency because of impaired ability to bind to EPCR (ie. normal amidolytic activity but reduced APC anticoagulant activity). To explore this possibility, the PC variants were purified from the conditioned medium of the stable cell lines and subjected to PC activation assays. As shown in Figure 3 , the activation rate of WT PC is ≈4-fold higher on HEK293 cells expressing EPCR and TM (gray bars) compared with that observed on HEK293 cells (white bars). Preincubation of the cells with an anti-EPCR antibody that blocks PC-EPCR interactions (JRK 1535; 500 nmol/L) inhibits the activation rate of WT PC on HEK293/EPCR/TM cells. The activation rate of PCArg9Cys is similar to that of WT PC, whereas PCArg-1Cys and PCVal34Met have impaired capacity to generate APC. Thus, patients carrying the PCArg-1Cys and PCVal34Met mutations have a type I and a type IIb heterozygous PC deficiency.
To analyze the PC-binding domain of EPCR, we sequenced exons 2 and 3 of PROCR, which encode for the PC-binding domain of EPCR. PCR amplification and sequencing of exons 2 and 3 were successful in all controls and in 630 of 653 and 649 of 653 patients, respectively. No SNVs were detected in exon 2 of PROCR in either the patients or the controls. As shown in Table 3 , we found 3 SNVs in exon 3 that occurred in the patients but not in the controls. The first SNV was a C to T transition at nt 6367, which results in a Arg96Cys substitution. The second SNV was a G to C transition at 6589, which results in a Val170Leu substitution. The third SNV was a silent mutation (C6519T). Within intron 2, we found 3 SNVs (G5212A, G5195A, and C5334A) in the patients but not in the controls. Within intron 3, we found a SNV (G deletion at 6738) that is present in both the patients and the controls, and a SNV (A6668T) that is present at a higher frequency in the patients than in the controls.
To determine whether the EPCR SNVs result in abnormal proteins with reduced binding affinity for PC, the cDNAs of WT EPCR and the 2 EPCR variants were stably transfected into HEK293 cells, and the ability of the EPCR variants to bind to fluorescently labeled APC was measured by flow cytometry. All 3 stable cell lines expressed similar levels of EPCR on the cell surface as confirmed by flow cytometry using an anti-EPCR antibody (JRK 1535; Figure 4 ). WT EPCR bound to fluorescently labeled APC with a K d value of 77±21 nmol/L, consistent with previous reports. 13, 19 In contrast, EPCR variants, Arg96Cys and Val170Leu, bound to fluorescently labeled APC with reduced affinities (K d values ≥2 µmol/L, which is higher than the circulating concentration of PC [≈60 nmol/L]). The binding curves obtained from the flow cytometry studies are shown in Figure 5 .
We also determined the prevalence of the previously reported PROCR A3 haplotype. 15 This haplotype results in substitution of Ser219 with Gly in the transmembrane domain of EPCR, which leads to increased endothelial shedding of EPCR and reduced EPCR function. 15 The PROCR A3 haplotype occurred at a significantly higher frequency in the patient group compared with the control group (P=0.001; Table 4 ). It should be noted that none of the carriers of the PROCR A3 haplotype were carriers of the PC or EPCR coding region SNVs described above.
Finally, we identified a 23-bp insertion in exon 3 of PROCR in 1 control individual, but not in any of the patients with VTE (insertion described in Table 1 ). Previous studies have shown that this insertion codes for 5 amino acids (YPQFL), which is followed by a stop codon, resulting in an abnormal EPCR protein that lacks part of the extracellular domain, the transmembrane domain, and the cytoplasmic tail. 20
Discussion
In this study, we explored the possibility that genetic mutations that impair PC-EPCR interactions may be associated with an increased risk of VTE. With respect to PROC, we identified 3 SNVs, each in individual patients, that result in mutations in the Gla domain of PC (PCArg-1Cys, PCArg9Cys, and PCVal34Met). The most common thrombophilic defects in the ELATE patients were Factor V Leiden, the prothrombin G20210A gene mutation, and antithrombin deficiency, with prevalences of 26.5% 9.3%, and 3.6%, respectively. 3 It should be noted that none of these 3 patients were carriers of the PC (µg/mL) Factor V Leiden gene, the prothrombin gene mutations, or had antithrombin deficiency.
Rate (mOD/min)
All 3 PROC SNVs have been reported previously (HGMD CM930604; HGMD CM950976; and HGMD CM920593). In this study, we showed that the 3 PC variants displayed reduced protein synthesis when expressed in HEK293 cells (Figure 1) , and thus are classified as type I deficiencies. Consistent with this observation, the PC antigen levels in the ELATE Study patients harboring the Val34Met, Arg9Cys, and Arg-1Cys mutations are lower than those in healthy volunteers and in the ELATE Study patients without PC mutations ( Figure 2 ). It is possible that warfarin may have reduced PC antigen levels in the 3 patients with, and the 18 patients without, the PROC mutations; however, the comparison of PC antigen levels between these 2 groups, and the finding of lower PC antigen levels in the 3 patients with the PROC mutations, should still be valid. Interestingly, the variants are secreted as a lower molecular weight form of ≈40 kDa (Figure 1 ). PC possesses 4 N-linked glycosylation sites: 1 is located in the first EGF domain (Asn 97), and 3 are located in the serine protease domain (Asn248, Asn313, and Asn 329). 18 α-PC, which is glycosylated at all 4 sites, accounts for ≈70% of plasma PC. In contrast, β-PC, which lacks glycosylation at Asn 329 and thus has a lower molecular weight, accounts for ≈30% of plasma PC. Previous studies suggest that the degree of glycosylation at Asn 329 is influenced by the correct post-translational processing of the Gla domain. 21 Thus, the presence of mutations within the Gla domain of the PC variants likely favors the formation of the β-form of PC. In patients, the presence of only the β-form of PC in plasma results in decreased anticoagulant activity. 22 Specifically, the naturally occurring PC N329T mutation results in an abnormal APC with impaired ability to inactivate Factor Va. The PCArg-1Cys and PCArg9Cys variants, both of which carry a free cysteine residue, have been shown to form a complex with α1-microglobulin. 23 Although we did not observe complexes between these PC variants and α1-microglobulin based on our Western blot analysis (presumably because HEK293 cells do not synthesize α1-microglobulin), it is possible that these complexes exist in the patient plasma.
We also observed that the PCArg-1Cys and PCVal34Met variants (secreted and purified from HEK293 cells) have reduced capacity to be converted to APC on the surface of TMand EPCR-expressing cells (Figure 3 ). This is consistent with previous studies that showed that mutation of Arg-1 to Cys in PC abolishes binding to EPCR. 24 Thus, patients harboring the PCArg-1Cys or PCVal34Met mutation would have a type I and a type II heterozygous PC deficiency. Physiologically, however, plasma levels of the PCArg-1Cys and PCVal34Met proteins would be very low, below that of the K d for PC-EPCR interactions (30 nmol/L). 1, 25 Therefore, the PCArg-1Cys and PCVal34Met mutations may result indirectly in a type II deficiency because of reduced plasma PC levels.
With respect to PROCR polymorphisms in the patients with VTE, we identified 2 SNVs that result in EPCR variants (Arg96Cys and Val170Leu). These SNVs have been reported previously (NCBI rs146420040 and NCBI rs61731003). In the current study, we demonstrated that introduction of either the Arg96Cys or the Val170Leu mutation results in abnormal EPCR protein with impaired ability to bind PC. Residues Arg96 and Val170 are located near residues that form hydrogen bonds between EPCR and Gla residues of PC. 12, 13 Although these EPCR variants do not bind to PC, they retain the ability to bind to JRK 1535 (a monoclonal antibody to EPCR), suggesting that the tertiary structure is maintained. In baboons, pretreatment with a monoclonal antibody to EPCR (which blocks PC binding) reduced the amount of thrombin-induced APC generation by 88%. 2 EPCR gene disruption in mice results in early embryonic lethality because of placental thrombosis. 26 Other polymorphisms in PROCR have been described. The first reported abnormality was a 23-bp insertion in exon 3 that leads to the production of a truncated EPCR, which does not bind to PC. 20 In the present study, we found this insertion in one of our control subjects. However, the clinical impact of this mutation is difficult to assess because of its low allelic frequency. 20, [27] [28] [29] [30] More recent studies have shown that soluble EPCR levels occur with a bimodal distribution in the normal population; ≈80% of subjects have low levels of soluble EPCR (<180 ng/mL), whereas ≈20% have high levels (between 200 and 700 ng/mL). 31, 32 Analysis of PROCR revealed that the A3 haplotype is over-represented in patients with VTE compared with the controls. 15 The A3 haplotype results in a Ser to Gly substitution in the transmembrane domain of EPCR that promotes cellular shedding of EPCR in endothelial cells. 33 In the current study, we confirmed that the EPCR A3 haplotype occurs at a significantly higher frequency in the patient group compared with the control group (P<0.001).
There are limitations to our study. First, the probability of finding 5 variants in the cases, but not in the controls, is P=0.062 (2-tailed Fischer exact test). Thus, the results of this study should be validated in larger studies of patients with unprovoked VTE. Second, the control population was younger in age than the ELATE patient. However, the cases and controls do have similar ethnicity and geographical background (predominantly whites), which may prevent false-positives because of population stratification.
To date, no common single nucleotide polymorphisms in the PROC and PROCR genes have been identified in genomewide association studies of VTE. [34] [35] [36] The results of a discovery genome-wide association studies for VTE in 1618 VTE cases of European origin confirmed well-known association of the FV Leiden variant and the ABO O blood group with VTE. [34] [35] [36] Additional genome-wide significant signals at the F11 region were associated with an increased risk of thrombosis. 36 Because genome-wide association studies cannot detect rare variants, the missing heritability for VTE risk may be because of clusters of rare variants. Our study suggests that rare variants in PROC and PROCR are more likely to be found in unprovoked VTE cases than in controls. Our data support the common disease, rare variant hypothesis that multiple rare variants, with functional effects and relatively high penetrance, are the major contributors to genetic susceptibility to a complex disease, such as VTE. 37, 38 Thus, high-throughput sequencing studies of candidate genes may emerge as a more accurate and powerful tool to elucidate the relationship between genetics and VTE. In summary, this is the first targeted DNA sequencing analysis of PROC and PROCR in a large group of patients with unprovoked VTE. We identified 5 SNVs in the coding regions of PROC and PROCR that are present in the patients, but not in the controls. Expression of the mutant proteins revealed impaired synthesis and/or reduced capacity for PC-EPCR interactions. We also validated previous findings that the EPCR A3 shedding haplotype is over-represented in patients with VTE. Our data suggest that genetic mutations that impair PC-EPCR binding interactions may increase the risk of VTE.
